logo
How to get the anti-ageing benefits of fasting without having to give up eating

How to get the anti-ageing benefits of fasting without having to give up eating

Yahoo6 days ago
Humans have been practising fasts for millennia. Our bodies are built to fast: 'It is literally the reason we carry body fat,' explains Dr Jason Fung, a nephrologist, fasting expert and the author of The Obesity Code. When the body goes into fasting mode it supports cellular rejuvenation and longevity. However, most of us cannot stick to an extended fast, drinking nothing but water, and still live a normal life.
Cue a little known molecule called spermidine, found in everything from blue cheese and mushrooms to wheat germ and soybeans, that is rapidly becoming one of most talked-about topics in longevity research. Some scientists even believe it may be one of the key reasons why some people live longer than others because it helps to rid the body of damaged cells linked to ageing.
'There is no other longevity compound on the market that packs as big a punch as spermidine. By activating the body's vital cell renewal and recycling process – called autophagy (which also occurs when you fast) – it targets ageing at the source. This looks like reduced inflammation, rejuvenated cells and enhanced hair growth, all a result of the cellular clean-up occurring within,' says Leslie Kenny, the founder of Oxford Healthspan and co-founder of the Oxford Longevity Project.
'I make a point of eating spermidine-rich food every day – such as lentils, beans, peas and mushrooms. I also add a food-derived spermidine supplement with the minimum effective daily dose (1mg) shown to improve memory in older adults with subjective cognitive decline,' she says.
Recent research backs up what she says.
And unlike some other longevity trends, spermidine isn't just for lab mice. Human studies, including a 13-year observational trial and several clinical studies in older adults, have linked higher spermidine intake with better memory, lower blood pressure and even a reduced risk of death.
Spermidine is a naturally occurring compound found in a variety of foods, especially those from plant sources and fermented products. Plants, animals and microbes produce spermidine naturally during metabolism. So, any fresh or unprocessed food will contain it to some degree.
What makes spermidine stand out is its ability to stimulate a process called autophagy, a kind of internal cellular spring-cleaning that clears out damaged cells and helps cells work more efficiently.
As we age, this process slows down, contributing to the development of chronic conditions like cancer, cardiovascular disease and neurodegeneration. But spermidine appears to reactivate autophagy even in older cells, offering a drug-free method of slowing ageing.
'Think of it as a molecular amplifier for health,' says Nektarios Tavernarakis, the author of a study in Nature Cell Biology into the health effects of spermidine. 'It helps cells tidy themselves, boosting resilience, energy production and potentially warding off disease.'
His research identified spermidine as essential to the longevity benefits of fasting. Fasting naturally increases autophagy, the body's cellular 'clean-up' process, and spermidine mimics and enhances this effect by promoting the same pathways.
This cellular renewal helps reduce age-related damage and inflammation.
Spermidine and brain health
Cognitive decline is one of the most feared consequences of ageing, but spermidine could offer hope. A clinical trial published in Alzheimer's & Dementia found that three months of spermidine supplementation improved memory in older adults with mild cognitive impairment. The SmartAge trial, published in GeroScience, also found improvements in memory and reductions in inflammatory markers in participants aged 60 to 90.
So, how does it work?
'Spermidine stimulates autophagy, which breaks down faulty proteins that otherwise accumulate in the brain and are linked to Alzheimer's disease,' explains Tavernarakis. This 'cellular housekeeping' clears the way for neurons to function better.
Andrew Steele, who worked at the Francis Crick Institute decoding DNA and author of Ageless: The New Science of Getting Older Without Getting Old, is cautiously optimistic: 'It's likely spermidine provides a general slowing of biological ageing. That may benefit the brain just as much as the heart or gut.'
He adds: 'In animal studies, it's helped restore cognitive and motor function. And in humans, we've seen memory improvements.'
'Evidence suggests those consuming more spermidine, mostly in a Mediterranean diet, have better brain (function) and higher life expectancy,' says Dr Stefan Kiechl, a professor of neurology at Innsbruck University, Austria, and one of the world's leading researchers into the health effects of spermidine.
How spermidine improves heart health
Heart disease remains the world's leading cause of death. New research suggests spermidine could also protect your heart.
In aged mice, spermidine supplementation has been shown to enhance heart elasticity, reduce fibrosis (stiffening) and improve mitochondrial function, which supports energy production within cells. 'It mimics some of the benefits of exercise and caloric restriction,' says Tavernarakis, who has studied spermidine's effects on cardiometabolic health.
'People with high spermidine intake tend to have lower blood pressure and a reduced risk of cardiovascular disease,' he says. A study from Nutrients (2024), using UK Biobank data, reported not only fewer heart attacks but a significant reduction in all-cause mortality for those with high dietary spermidine.
'In our population studies, individuals with higher spermidine consumption, primarily from Mediterranean diets, had better heart health,' notes Kiechl. 'And the anti-inflammatory effects may also play a key role.'
Other studies support his claim and a 2024 UK Biobank study also linked higher polyamine intake with fewer heart problems and an 18 per cent reduction in early death.
Spermidine and cancer
Emerging research highlights spermidine's potential in cancer prevention through several mechanisms. By triggering autophagy, spermidine can lower the chance of cells turning cancerous. A 2018 review in Nature Reviews Cancer found how autophagy can prevent the initiation of tumours by maintaining healthy cells in the body.
Spermidine also supports immune function, particularly by rejuvenating T cells, which are crucial for identifying and eliminating cancer cells. A 2020 study published in Nature Communications demonstrated that spermidine supplementation restored T cell function in aged mice, improving immune surveillance against tumours.
Spermidine and gut health
Another area where spermidine shows promise is the gut, particularly through its influence on the gut microbiome.
The gut plays a dual role when it comes to spermidine. It is where spermidine from food gets absorbed into the body. But also many of the beneficial microbes in your digestive system, especially in the colon, naturally produce spermidine as part of their normal activity.
'Because it boosts autophagy, spermidine supports the gut barrier and helps maintain healthy microbial balance,' says Steele. 'This could be important for preventing chronic gut inflammation and related disorders like inflammatory bowel disease or metabolic syndrome.'
Although research is still in the early stages, some studies suggest that spermidine may help keep the lining of the gut strong and intact, preventing harmful substances, like toxins, bacteria and partially digested food particles, from leaking into the body and triggering inflammation. There is also evidence that it helps gut-residing immune cells function better, which could be especially beneficial as we age.
Adding spermidine to your diet
One of the easiest and safest ways to get more spermidine is through your diet. Aged cheese, mushrooms, soy products, whole grains and legumes are all good sources. Wheat germ is especially high in spermidine, which you can sprinkle on your yogurt or cereal at breakfast.
A tablespoon of wheat germ provides around 1.2 milligrams of spermidine, and 100g of mushrooms or cheddar can offer up to 10mg.
Studies suggest that a daily intake of 5mg to 10mg may support health benefits, which can be achieved through a balanced mix of these foods consumed regularly throughout the week.A large US study found that people with the highest spermidine intake from foods like cereals, vegetables, legumes and cheese had significantly lower risks of cardiovascular disease and all-cause mortality.
Kiechl advises a measured approach for now. 'Evidence is strong but there are no 'gold standard' large-scale intervention trials which are necessary for standard medical recommendations,' he says.
As spermidine is naturally found in a wide range of everyday foods, it should be easy to boost intake if you don't want to use supplements.
That said, for those who prefer a more targeted approach, there are now a number of spermidine supplements on the market that are specifically tested for purity, safety and consistency. These supplement options provide a potential alternative for those who want to explore spermidine's health benefits in a measured, evidence-aware way, while science continues to catch up.
Kenny says spermidine has had a dramatic impact on her health, after she was diagnosed with lupus, rheumatoid arthritis and Hashimoto's thyroiditis in her late 30s. 'The biggest area has been in my hsCRP (high-sensitivity C-reactive protein), a biomarker of systemic inflammation in the body. Mine is 0.3 – the same as a healthy teenager. In addition, my biological age, as measured by the GlycanAge test, which measures many other inflammatory markers, shows my biological age as 21. This matters because at 39, I was told inflammation in my body was so out of control, I had only five years left to live.
'Other places I notice are my hair quality and colour – I am 60 and don't dye my hair, or need any hair treatments, because my hair, lashes and brows are all healthy and growing as they would when I was younger. I also get consistently strong deep-sleep scores (60-plus minutes) on my Oura Ring when I take it before bed. This is important because it's only during deep sleep that the glymphatic system, the brain's 'washing machine', gets to work to remove the rubbish that piles up during the day that is associated with dementia.'
Spermidine supplements
Primeadine Original spermidine, from Oxford Healthspan, co-founded by Leslie Kenny, is developed in Japan from non-GMO wheat germ and is third-party laboratory tested.
Longevity Box offers a plant-based spermidine supplement aimed at supporting cellular renewal and healthy ageing.
UK-based Youth & Earth also offers a well-regarded spermidine supplement made from high-grade wheat germ extract.
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies
Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies

Yahoo

time8 minutes ago

  • Yahoo

Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies

· Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements. Ingelheim, Germany, Tampa, Florida, USA, and Belfast, Northern Ireland, UK [28 July 2025] – Boehringer Ingelheim and Re-Vana Therapeutics, a US and UK based developer of ocular therapeutics and ocular drug delivery technologies, today announced a strategic collaboration and license agreement that aims to develop first-in-class extended-release therapies for eye diseases. Globally, millions of people living with eye health conditions face a progressive decline in their independence and connection to the world due to vision loss. With its diverse pipeline in eye health, which includes four assets in Phase II, Boehringer Ingelheim is committed to preserving the retina, protecting people's way of life and preventing vision loss. Treating ophthalmic diseases often requires frequent injections directly into the eye, which can be very burdensome for patients. Re-Vana's drug delivery technology is designed to release treatments slowly over six to 12 months, aiming to drastically reduce how often patients need injections. Lowering the treatment burden could lead to higher treatment compliance, and potentially result in better therapeutic outcomes. Boehringer Ingelheim will explore combining this technology with its unique pipeline in eye health. 'We're looking forward to team up with Re-Vana to push the boundaries of what's possible in eye health,' said Nedim Pipic, Global Head of Mental Health, Eye Health and Emerging Areas at Boehringer Ingelheim. 'Together, we want to tackle the limits of today's treatments – aiming to help people keep their sight, with fewer injections. This partnership is a bold step forward in our mission to protect vision and ease the burden on patients.' 'The strategic collaboration with Boehringer Ingelheim marks a transformational moment for Re-Vana,' said Michael O'Rourke, Re-Vana Chief Executive Officer. 'By combining our extended-release platform with Boehringer Ingelheim's world-class research and development capabilities and eye health pipeline, we strive to bring forward a new generation of long-acting treatments for eye diseases that offer clinical and quality-of-life benefits for patients.' Under the collaboration, Boehringer Ingelheim aims to add up to three projects per year across therapeutic modalities. The companies will jointly oversee Re-Vana's feasibility and development activities for the extended-release programs, with Boehringer Ingelheim assuming sole responsibility for clinical development, regulatory approval, and global commercialization of the products. The terms of the agreement grant Boehringer Ingelheim target exclusivity, and provide for upfront, development, regulatory and commercial milestone payments to Re-Vana, with total potential deal value exceeding $1 billion for the initial three targets, in addition to royalty payments on net sales. Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at (Global) or (UK). About Re-Vana Therapeutics Re-Vana Therapeutics Ltd, founded in 2016 as a spin-out from Queen's University Belfast, is an ocular therapeutics and innovative ocular drug delivery company based in Belfast, Northern Ireland, and a wholly owned subsidiary of Re-Vana Holding, Inc., Tampa, Florida. Re-Vana is venture backed with leading US Ophthalmic investors including Visionary Ventures, ExSight Ventures, InFocus Capital Partners and UK investors including QUBIS, TechStart Ventures, Invest Northern Ireland and Clarendon Fund Managers. Re-Vana is currently raising a Series B round for their sustained release anti-VEGF asset. Learn more at Intended Audiences Notice This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business. Media Contacts Boehringer Ingelheim: Dr. Reinhard MalinBoehringer Ingelheim Corporate Center GmbH Innovation Unit/Bio Comms, Corp. Affairs Media + PR press@ Linda RuckelBoehringer IngelheimInnovation Unit Re-Vana: Michele Gray Gray Communications, LLCMichele@ 917 449 9250Sign in to access your portfolio

FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency
FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency

Yahoo

time8 minutes ago

  • Yahoo

FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency

First of many planned label expansions supporting Vision 2030 goal to become the leading endocrinology rare disease company On track to initiate basket trial for ISS, SHOX deficiency, Turner syndrome, and SGA*, as well as combination therapy trials in achondroplasia and hypochondroplasia, in Q4 2025 COPENHAGEN, Denmark, July 28, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has approved SKYTROFA® (lonapegsomatropin-tcgd; developed as TransCon hGH) for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD), a rare disorder resulting from decreased or total loss of growth hormone production. Lonapegsomatropin (approved by the FDA in 2021 for the treatment of pediatric GHD) is a prodrug of somatropin (human growth hormone, or hGH) administered once weekly, providing sustained release of active, unmodified somatropin. The FDA's approval of SKYTROFA for adult GHD was based on results from foresiGHt, a Phase 3 randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled (open-label) clinical trial that compared the efficacy and safety of weekly TransCon hGH with weekly placebo and daily somatropin in adults with GHD. 'The abnormal body composition, dyslipidemia, and insulin resistance that are the hallmarks of adult GHD predispose affected individuals to serious medical complications such as metabolic syndrome, increased cardiovascular risk, and impaired quality of life – including cognitive dysfunction, depression, anxiety, sleep disturbance, and reduced physical and mental drive. Despite this, adherence to daily somatropin injections that have been the standard of care for more than 25 years remains a problem,' said Kevin Yuen, M.D., Barrow Neurological Institute, University of Arizona College of Medicine and Creighton University School of Medicine in Phoenix, Arizona. 'It is no surprise that patients are looking for a less burdensome treatment regimen, and a new treatment option such as SKYTROFA, with once-weekly injection and its unique release of unmodified somatropin, is expected to help improve both real-world adherence and overall outcomes.' 'Our market research shows SKYTROFA is the treatment of choice for pediatric GHD among patients and physicians, and we are pleased to expand its availability in the United States for the treatment of adults initiating therapy or switching from another growth hormone therapy,' said Jan Mikkelsen, President and Chief Executive Officer at Ascendis Pharma. 'This important milestone is the first of many planned label expansions supporting our goal to become the leading endocrinology rare disease company.' The following information is intended for the U.S. Audience Only: IMPORTANT SAFETY INFORMATION & USES SKYTROFA is a prescription medicine used for: the replacement of growth hormone in children 1 year old or older who weigh at least 26 pounds (11.5 kilograms) with growth hormone deficiency (GHD) the replacement of growth hormone in adults with growth hormone deficiency (GHD) Do not take SKYTROFA if: you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing problems you are allergic to somatropin or any of the ingredients in SKYTROFA you are a child with closed bone growth plates you have cancer or other tumors you have certain types of eye problems caused by diabetes you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea (briefly stopping breathing during sleep) Tell your healthcare provider if you are pregnant or plan to become pregnant, about all of your medical conditions, and about all the medicines you take. SKYTROFA may affect how other medicines work, and other medicines may affect how SKYTROFA works. What are the possible side effects of SKYTROFA? SKYTROFA may cause serious side effects, including: serious allergic reactions. Get medical help right away if you have swelling of the face, mouth, tongue, or throat or trouble breathing high risk of death in people who have critical illnesses caused by heart or stomach surgery, trauma, or serious breathing problems increased risk of growth of an existing tumor or cancer, or increased risk of a previous tumor or cancer returning in people who were treated with radiation to the brain or head as children and who developed low growth hormone problems Your healthcare provider will need to monitor for the growth or return of a tumor or cancer. Contact your healthcare provider if you start to have sudden changes in behavior, headaches, vision problems, or changes in moles, birthmarks, or skin color new or worsening high blood sugar or diabetes. Your blood sugar may need to be monitored during treatment with SKYTROFA increase in pressure in the skull. Contact your healthcare provider if headaches, eye problems, nausea, or vomiting occur too much fluid in the body (fluid retention). Contact your healthcare provider if you notice swelling in the hands and feet, pain in the joints or muscles, or nerve problems that cause pain, burning or tingling in the hands, arms, legs, and feet decrease in a hormone called cortisol. Your healthcare provider will do blood tests to check your cortisol levels decrease in thyroid hormone levels. Decreased thyroid hormone levels may affect how well SKYTROFA works. Your healthcare provider will do blood tests to check your thyroid hormone levels hip and knee pain or a limp in children (slipped capital femoral epiphysis). This may lead to a serious condition where bone tissue dies due to a lack of blood supply (osteonecrosis). Get medical help right away for children who develop a limp or have hip or knee pain worsening of curvature of the spine in children (scoliosis) severe and constant abdominal pain. This could be a sign of pancreatitis. Tell your healthcare provider about any new abdominal pain loss of fat and tissue weakness in the area of skin you or your child inject. Talk to your healthcare provider about rotating the areas where SKYTROFA is injected high risk of sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems, including sleep apnea increase in phosphate, alkaline phosphatase, and parathyroid hormone levels in your blood. Your healthcare provider will do blood tests to check this The most common side effects of SKYTROFA in children include: viral infection, fever, cough, nausea and vomiting, bleeding, diarrhea, stomach area pain, joint pain and arthritis The most common side effects of SKYTROFA in adults include: swelling due to fluid build-up and low thyroid hormone These are not all of the possible side effects of SKYTROFA. Call your doctor for medical advice about side effects. You are encouraged to report side effects to FDA at 1-800-FDA-1088 or at You may also report side effects to Ascendis Pharma at 1-844-442-7236. Please click here for SKYTROFA full Prescribing Information. About Ascendis Pharma A/SAscendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit to learn more. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis' future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis' plans to initiate basket trial for ISS, SHOX deficiency, Turner syndrome, and SGA, as well as combination therapy trials in achondroplasia and hypochondroplasia, in Q4 2025, (ii) SKYTROFA's ability to improve real-world adherence and overall outcomes, (iii) Ascendis' planned label expansions for SKYTROFA, (iv) Ascendis' goal of becoming the leading endocrinology rare disease company, (v) Ascendis' ability to apply its TransCon technology platform to make a meaningful difference for patients, and (vi) Ascendis' application of its TransCon technologies to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis' products and product candidates; unforeseen safety or efficacy results in Ascendis' development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis' development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis' business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis' ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors, including tariffs and trade policies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis' business in general, see Ascendis' Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis' other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and SKYTROFA® are trademarks owned by the Ascendis Pharma group. © July 2025 Ascendis Pharma A/S. Investor Contacts:Sarada WeerasingheAscendis Pharmair@ Media Contact:Melinda BakerAscendis Pharmamedia@ Patti BankICR Healthcare+1 (415) ----* ISS = idiopathic short statureSHOX deficiency = short stature homeobox-containing gene deficiencySGA = small for gestational ageSign in to access your portfolio

UK National Health Service Productivity Lags as Doctors Strike
UK National Health Service Productivity Lags as Doctors Strike

Bloomberg

time11 minutes ago

  • Bloomberg

UK National Health Service Productivity Lags as Doctors Strike

Britain's National Health Service is almost a tenth less productive than before the pandemic, official figures show, a performance that will renew concerns about value-for-money for the taxpayer amid a fresh wave of doctor strikes. Analysis by the Office for National Statistics revealed that health-care productivity in the UK was 8.8% lower last year than in 2019. As the NHS accounts for 39% of total UK public spending, its problems weighed heavily on the public sector as a whole. Total public-service productivity, which includes education, defense and policing, was 4.2% lower than five years earlier, before Covid hit.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store